Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats

Neuropsychopharmacology

Volumn 32, Issue 2, 2007, Pages 284-288

  Raskind, Murray A ^a,b   Burke, Brianna L ^b   Crites, Norman J ^b   Tapp, Andre M ^a,b   Rasmussen, Dennis D ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic drug; Melatonin; Obesity; Olanzapine; Schizophrenia

Indexed keywords

MELATONIN; OLANZAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FEMALE; FLUID INTAKE; FOOD INTAKE; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; INTRAABDOMINAL FAT; LOCOMOTION; MESENTERY; NONHUMAN; OBESITY; OMENTUM; PRIORITY JOURNAL; RAT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

ABDOMINAL FAT; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; ENERGY METABOLISM; FEMALE; LIPID METABOLISM; MELATONIN; OBESITY; PINEAL GLAND; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; UP-REGULATION; WEIGHT GAIN;

EID: 33846247904     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301093     Document Type: Article

References (30)

1. Allison DB, Mackell JA, McDonnell DD (2003). The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 54: 565-567.
2. American Diabetes Association (2004). Consensus development conference on antipsychotic drugs and obesity in diabetes. Diabetes Care 27: 596-601.
3. Cagnacci A (1996). Melatonin in relation to physiology in adult humans. J Pineal Res 21: 200-213.
4. Fontaine KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE et al(2001). Estimating the consequences of antipsychotic induced weight gain on health and mortality rate. Psychiatry Res 101: 277-288.
5. Gao X-M, Sakai K, Tamminga CA (1998). Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol. Neuropsychopharmacology 19: 428-433.
6. Glazer G (2001). Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med 161: 1814-1824.
7. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L et al (2002). Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 159: 1055-1057.
8. Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO (2005a). Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 162: 1744-1746.
9. Graham KA, Perkins DO, Edwards LJ, Barrier Jr RC, Lieberman JA, Harp JB (2005b). Effect on olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 162: 118-123.
10. Grad BR, Rozencwaig R (1993). The role of melatonin and serotonin in aging: update. Psychoneuroendocrinology 18: 283-295.
11. Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD et al(2005). A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 162: 954-962.
12. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD (2001). Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62: 92-100.
13. Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK et al(1982). Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 54: 254-260.
14. Krotkiewski M, Björntop P, Sjostrom L, Smith U (1983). Impact of obesity on metabolism in men and women: importance of regional adipose tissue distribution. J Clin Invest 72: 1150-1162.
15. Leucht S, Pischel-Wulz G, Abraham D, Kissling W (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo: a metaanalysis of randomized controlled trials. Schizophr Res 35: 51-68.
16. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al(2005). Effectivenss of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
17. Mann K, Rossbach W, Muller MJ, Muller-Siecheneder F, Pott T, Linde I et al(2006). Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 31: 256-264.
18. Monteleone P, Maj M, Fusco M, Kemali D, Reiter RJ (1992). Depressed nocturnal plasma melatonin levels in drug-free paranoid schizophrenics. Schizophr Res 7: 77-84.
19. Mukherjee S, Decina P, Bocola V, Saracini F, Scapicchio PL (1996). Diabetes mellitus in schizophrenic patients. Compr Psychiatry 37: 68-73.
20. Nelson RJ, Demas GE (1997). Role of melatonin in mediating seasonal energetic and immunologic adaptations. Brain Res Bull 44: 423-430.
21. Peschke D, Peschke E, Mess B (1987). Circannual rhythm and increase in body weight and food intake in the young wistar rat following pinealectomy and ganglioectomy. Neuroendocrinol Lett 9: 321-327.
22. Puchalski SS, Green JN, Rasmussen DD (2003). Melatonin effect on rat body weight regulation in response to high fat diet at middle age. Endocrine 21: 163-167.
23. Rasmussen DD, Boldt BM, Wilkinson CW, Yellon SM, Matsumoto AM (1999). Daily melatonin administration at middle age suppresses male rat visceral fat, plasma leptin, and plasma insulin to youthful levels. Endocrinology 140: 1009-1012.
24. Rasmussen DD, Mitton DR, Larsen SA, Yellon SM (2001). Aging-dependent changes in the effect of daily melatonin supplementation on rat metabolic and behavioral responses. J Pineal Res 31: 89-94.
25. Ryan MC, Collins P, Thakore JH (2003). Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am J Psychiatry 160: 284-289.
26. Stein MB, Kline NE, Matloff JL (2002). Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 159: 1777-1779.
27. Stetson MH, Sarafidis E, Rollag MD (1986). Sensitivity of adult male Djungarian hamsters (Phodopus sungonus suugorus) to melatonin injections through the day: effects on the reproductive system and the pineal. Biol Reprod 35: 618-623.
28. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J et al(1999). Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60: 358-363.
29. Wolden-Hanson T, Mitton DR, McCants RL, Yellon SM, Wilkinson CW, Matsumoto AM et al(2000). Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology 141: 487-497.
30. Zurlo F, Lillioja S, Esposito-Del Puente A, Nyomba BL, Raz I, Saad MF et al(1990). Low ratio of fat to carbohydrate oxidation as a predictor of body weight gain: study of 24th RQ. Am J Physiol 259: E650-E657.